To overcome the limitations, recent strategies have focused on enhancing endogenous retinoic acid levels by inhibiting its enzymatic breakdown. Specific CYP26 inhibitors, such as liarozole and talarozole, have demonstrated improved tolerability and efficacy in medical applications compared to traditional retinoid therapies (9).
Chios mastic enhances retinoic acid activity through CYP26A1 inhibition
One notable plant-based alternative is mastic, a natural resin from the Pistacia lentiscus tree, traditionally known as the “Gold of Chios.” Valued for its numerous valuable ingredients (10), its antibacterial, anti-inflammatory, antioxidant, and anticancer properties (11), and also for its wound healing capacities (12), Chios mastic is sustainably harvested and recognized for its cultural and therapeutic significance (13).
Unlike conventional alternatives that merely mimic the effects of retinol, mastic active ingredient introduces a novel approach by targeting the metabolic regulation of retinoic acid. Retinoic acid can induce its own degradation by upregulating CYP26 enzymes, particularly CYP26A1, which converts it into inactive metabolites. In keratinocytes, CYP26A1 plays a key role in this degradation process (8).
By inhibiting CYP26A1, mastic active ingredient increases endogenous retinoic acid levels, leading to activation of RXR (Retinoid X Receptor) and RAR (Retinoic Acid Receptor) nuclear receptors (1, 14), which function as transcription factors to modulate the expression of specific genes involved in skin rejuvenation and impure skin improvement (Figure 1).
By maintaining natural retinoic acid levels in the skin, mastic enhances efficacy without requiring high concentrations. This upstream mechanism supports the skin’s intrinsic retinoid activity and delivers benefits like improved texture, reduced lines, and enhanced cell turnover, while minimizing irritation. As a result, Chios mastic is especially suitable for sensitive skin and natural skincare. Its development offers a next-generation plant-based retinol alternative that overcomes conventional limitations.

This randomized, placebo-controlled half-face study was done with 23 volunteers (Asian, female) aged 21 to 48 years (mean age: 28.3 y) having oily skin and impurities. They applied a cream containing 2 % mastic active ingredient or a placebo twice daily for 14 days. Measured parameters on day 0, 7 and 14 were sebum output (Sebumeter® SM810) measured on the forehead, skin hydration (Corneometer® CM825) measured in the cheek region, and standardized facial photography (VISIA® CR).
28-day clinical study on the anti-ageing efficacy of mastic active ingredient
This randomized, placebo-controlled study involved 18 volunteers (Caucasian, female) aged 42 to 70 years (mean age: 57 y). They applied a cream containing 2 % mastic active ingredient or a placebo to one half of the face and the inner sides of each forearm twice daily for 28 days. The measured parameters were skin elasticity on the face (Cutometer® dual MPA 580, Courage + Khazaka, Germany) and density on the forearms using the Dermalab® Ultrasound system (Cortex Technology, Denmark).
28-day clinical study on the scalp-care efficacy of mastic active ingredient
This randomized, placebo-controlled trial included a total of 42 volunteers (Caucasian, female & male), aged 18 to 68 years (mean age: 46.5 y), all with oily scalp and visible dandruff. Volunteers were split into two groups and applied either a leave-on serum with 1 % mastic active ingredient or a placebo serum once daily to the entire scalp and massaged in thoroughly. The parameters were visible scalp dandruff (Aramo® ASW 300F system, 60 x magnification) and Malassezia occurrence (microbiota samples collected from the neck using sterile swabs). Swabs were streaked onto plates (ChromAgar medium) and incubated for 72 h at 30-37±1 °C under aerobic atmosphere. Grown colonies were transferred to Columbia Agar and, after microscopic preparation (Gram staining), analysed through biochemical and enzymatic tests to identify and quantify microbial strains. Malassezia was not present in all participants: it was detected in 12 individuals in the group using mastic active ingredient and in 14 individuals in the placebo group. Microbiota analysis was therefore conducted on these 26 volunteers. Dandruff severity was quantified using numeric values derived from the macrophotographs.

Figure 2. Reduction of skin impurities after 28 days









- Zasada M, Budzisz E. Retinoids: active molecules influencing skin structure formation in cosmetic and dermatological treatments. Postepy Dermatol Alergol. 2019;36(4):392-7. https://pubmed.ncbi.nlm.nih.gov/31616211/
- van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther. 2006;19(5):252-63. https://onlinelibrary.wiley.com/doi/10.1111/j.1529-8019.2006.00082.x
- Temova Rakusa Z, Skufca P, Kristl A, Roskar R. Retinoid stability and degradation kinetics in commercial cosmetic products. J Cosmet Dermatol. 2021;20(7):2350-8. https://pubmed.ncbi.nlm.nih.gov/33206444/
- Yin S, et al. Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity. J Clin Invest. 2013;123(9):3941-51. https://pubmed.ncbi.nlm.nih.gov/23925292/
- Failloux N, Bonnet I, Perrier E, Baron MH. Effects of light, oxygen and concentration on vitamin A1. J Raman Spectrosc. 2004;35(2):140-7. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jrs.1116
- Mukherjee S, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-48. https://pubmed.ncbi.nlm.nih.gov/18046911/
- Zhong J, Zhao N, Song Q, Du Z, Shu P. Topical retinoids: Novel derivatives, nano lipid-based carriers, and combinations to improve chemical instability and skin irritation. J Cosmet Dermatol. 2024;23(10):3102-15. https://pubmed.ncbi.nlm.nih.gov/38952060/
- Heise R, et al. Skin retinoid concentrations are modulated by CYP26AI expression restricted to basal keratinocytes in normal human skin and differentiated 3D skin models. J Invest Dermatol. 2006;126(11):2473-80. https://pubmed.ncbi.nlm.nih.gov/16778795/
- Verfaille CJ, Borgers M, van Steensel MA. Retinoic acid metabolism blocking agents (RAMBAs): a new paradigm in the treatment of hyperkeratotic disorders. J Dtsch Dermatol Ges. 2008;6(5):355-64. https://pubmed.ncbi.nlm.nih.gov/17941881/
- Panagiota S, et al. Revealing the Potential of Chios Mastic Gum and Its Constituents for Cosmetic Applications through Chemical Profiling and Biological Evaluation. Cosmetics. 2024;11(5):155. https://www.mdpi.com/2079-9284/11/5/155
- Dimas KS, Pantazis P, Ramanujam R. Review: Chios mastic gum: a plant-produced resin exhibiting numerous diverse pharmaceutical and biomedical properties. In Vivo. 2012;26(5):777-85. https://pubmed.ncbi.nlm.nih.gov/22949590/
- Haghdoost F, et al. Pistacia atlantica Resin Has a Dose-Dependent Effect on Angiogenesis and Skin Burn Wound Healing in Rat. Evid Based Complement Alternat Med. 2013;2013:893425. https://pubmed.ncbi.nlm.nih.gov/24285978/
- Pachi VK, et al. Traditional uses, phytochemistry and pharmacology of Chios mastic gum (Pistacia lentiscus var. Chia, Anacardiaceae): A review. J Ethnopharmacol. 2020;254:112485. https://pubmed.ncbi.nlm.nih.gov/32092498/
- Szymanski L, et al. Retinoic Acid and Its Derivatives in Skin. Cells. 2020;9(12). https://pubmed.ncbi.nlm.nih.gov/33322246/
- Eisenstein M. The skin microbiome. Nature. 2020;588(7838):S209. https://www.nature.com/articles/d41586-020-03523-7
About the author

Eva Boenzli
Scientific Project Manager, Mibelle Biochemistry, Switzerland
Eva Bönzli studied biology at the University of Basel and earned her PhD at the University of Zurich on the topic of entry mechanisms of viruses into their host cells. After two postdocs at the University of Southern Denmark (SDU) and ETH Zurich on liposome fusions, she joined Mibelle Biochemistry. There, as a scientific project manager in the research team, she plans in vitro and in vivo efficacy studies for cosmetic active ingredients for skin and hair.
























